{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:54Z","timestamp":1790108814625,"version":"4.0.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["09150162310191"],"award-info":[{"award-number":["09150162310191"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijantimicag.2025.107537","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:42:57Z","timestamp":1747122177000},"page":"107537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The importance of drug exposure in the development of cytomegalovirus resistance"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3859-4553","authenticated-orcid":false,"given":"Katie","family":"Lynch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6478-1959","authenticated-orcid":false,"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijantimicag.2025.107537_bib0001","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.3390\/microorganisms11102372","article-title":"Antiviral approach to cytomegalovirus infection: an overview of conventional and novel strategies","volume":"11","author":"Bottino","year":"2023","journal-title":"Microorganisms"},{"issue":"3","key":"10.1016\/j.ijantimicag.2025.107537_bib0002","doi-asserted-by":"crossref","first-page":"e2034","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0003","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0004","unstructured":"WHO collaborating centre on Donation and Transplantation. 2022 data based on the Global Observatory on Donation Transplantation (GODT). https:\/\/www.transplant-observatory.org; 2022. Accessed May 28, 2025."},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0005","doi-asserted-by":"crossref","first-page":"1196564","DOI":"10.3389\/fonc.2023.1196564","article-title":"Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation","volume":"13","author":"Salhotra","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0006","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ijantimicag.2025.107537_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13977","article-title":"Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the International CMV Symposium 2021","volume":"24","author":"Kotton","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0009","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1016\/j.transproceed.2011.05.007","article-title":"Influence of cytomegalovirus disease in outcome of solid organ transplant patients","volume":"43","author":"Linares","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.transproceed.2004.03.085","article-title":"Cytomegalovirus disease latent and active infection rates during the first trimester after kidney transplantation","volume":"36","author":"Schroeder","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0011","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1399-3062.2010.00584.x","article-title":"Diversity of antiviral-resistant human cytomegalovirus in heart and lung transplant recipients","volume":"13","author":"Iwasenko","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0013","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0014","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1128\/AAC.02130-15","article-title":"Contribution of population pharmacokinetics to dose optimization of ganciclovir-valganciclovir in solid-organ transplant patients","volume":"60","author":"Padull\u00e9s","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0016","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0017","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients","volume":"26","author":"Scott","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0019","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/jac\/dkab419","article-title":"Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads","volume":"77","author":"M\u00e4rtson","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0020","doi-asserted-by":"crossref","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0021","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/psp4.12593","article-title":"Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients","volume":"10","author":"Prohn","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.ijantimicag.2025.107537_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02405-21","article-title":"New perspectives on antimicrobial agents: maribavir","volume":"66","author":"Halpern-Cohen","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0023","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJM199112053252303","article-title":"Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation","volume":"325","author":"Goodrich","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0024","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2016.031","article-title":"CMV in hematopoietic stem cell transplantation","volume":"8","author":"De la Camara","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0025","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1353\/pbm.2011.0027","article-title":"Compassionate use: a story of ethics and science in the development of a new drug","volume":"54","author":"Buhles","year":"2011","journal-title":"Perspect Biol Med"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0026","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/cid\/cis1035","article-title":"Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients","volume":"56","author":"Le Page","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0027","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.1086\/cid\/32.9.ii","article-title":"Valganciclovir, a more potent oral therapy for CMV retinitis in AIDS, approved by FDA","volume":"32","author":"Kaye","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0028","doi-asserted-by":"crossref","first-page":"e01855","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0029","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0031","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0032","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/idr16010005","article-title":"Management of cytomegalovirus infections in the era of the novel antiviral players, letermovir and maribavir","volume":"16","author":"Piret","year":"2024","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10332","article-title":"Cytomegalovirus management in solid organ transplant recipients: a pre-COVID-19 survey from the Working Group of the European Society for Organ Transplantation","volume":"35","author":"Grossi","year":"2022","journal-title":"Transpl Int"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0034","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","article-title":"American Society for Transplantation and Cellular Therapy Series: #3\u2014prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation","volume":"27","author":"Hakki","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V99.4.1159","article-title":"Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation","volume":"99","author":"Reusser","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0036","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-010-0569-x","article-title":"Cytomegalovirus infection\/disease after hematopoietic stem cell transplantation","volume":"91","author":"Mori","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0037","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"\u00c5sberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0038","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003495-200161080-00016","article-title":"Ganciclovir","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0039","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.transproceed.2023.11.021","article-title":"Low-dose vs standard-dose valganciclovir for cytomegalovirus prophylaxis after kidney transplantation: a single-center retrospective analysis","volume":"56","author":"Farkas","year":"2024","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0040","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/eri.12.115","article-title":"Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients","volume":"10","author":"Bacigalupo","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0041","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0042","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/sur.2015.266","article-title":"Use of cidofovir for cytomegalovirus disease refractory to ganciclovir in solid organ recipients","volume":"18","author":"Bonatti","year":"2017","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0043","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0044","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0045","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.transproceed.2017.09.058","article-title":"Resistant cytomegalovirus infection after renal transplantation: literature review","volume":"50","author":"Cintra-Cabrera","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0046","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0047","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00134-024-07737-5","article-title":"What intensivists need to know about cytomegalovirus infection in immunocompromised ICU patients","volume":"51","author":"Fern\u00e1ndez","year":"2025","journal-title":"Intensive Care Med"},{"issue":"7","key":"10.1016\/j.ijantimicag.2025.107537_bib0048","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/v16071085","article-title":"Refractory\/resistant cytomegalovirus infection in transplant recipients: an update","volume":"16","author":"Royston","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0049","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes","volume":"85","author":"Chevillotte","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0050","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.clinthera.2017.07.005","article-title":"A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients","volume":"39","author":"Chong","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0051","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor\u2013Based immunosuppression? A systematic review and meta-analysis","volume":"94","author":"Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0052","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2018.03.111","article-title":"Outcomes associated with mammalian target of rapamycin (mTOR) inhibitors in heart transplant recipients: a meta-analysis","volume":"265","author":"Jennings","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0053","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/phar.2799","article-title":"The incidence of cytomegalovirus and BK polyomavirus infections in kidney transplant patients receiving mTOR inhibitors: a systematic review and meta-analysis","volume":"43","author":"Ye","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0054","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.3390\/jcm11144216","article-title":"Effect of sirolimus vs. everolimus on CMV-infections after kidney transplantation\u2014a network meta-analysis","volume":"11","author":"Wolf","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0055","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10741-020-09967-3","article-title":"Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens","volume":"27","author":"Ueyama","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.ijantimicag.2025.107537_bib0056","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13267","article-title":"Infections after kidney transplantation: a comparison of mTOR-is and CNIs as basic immunosuppressants. A systematic review and meta-analysis","volume":"22","author":"Wolf","year":"2020","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2025.107537_bib0057","first-page":"CD004290","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"12","author":"Hahn","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0058","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5414\/CN109287","article-title":"Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: a systematic review and meta-analysis","volume":"89","author":"He","year":"2018","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0059","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor\u2013based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0060","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s11255-014-0783-1","article-title":"Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis","volume":"46","author":"Su","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0061","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.transproceed.2017.02.046","article-title":"Ganciclovir dosing strategies and development of cytomegalovirus resistance in a kidney transplant recipient: a case report","volume":"49","author":"Echenique","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0062","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0063","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rmv.1873","article-title":"Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: current state of the art","volume":"26","author":"Campos","year":"2016","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0064","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0065","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cmi.2015.06.009","article-title":"Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ijantimicag.2025.107537_bib0066","doi-asserted-by":"crossref","first-page":"e02337","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0067","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0068","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ijantimicag.2025.107537_bib0069","doi-asserted-by":"crossref","first-page":"e1287","DOI":"10.1093\/infdis\/jiae287","article-title":"Cytomegalovirus antiviral resistance among Kidney transplant recipients in a phase 3 trial of letermovir vs valganciclovir prophylaxis","volume":"230","author":"Strizki","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0070","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jiad293","article-title":"Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients","volume":"229","author":"Chou","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0071","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s11255-012-0293-y","article-title":"The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation","volume":"45","author":"Bedino","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0072","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/TP.0b013e31828555ac","article-title":"Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations","volume":"95","author":"Gracia-Ahufinger","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0073","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1093\/ofid\/ofaa439.776","article-title":"Safety and efficacy of high-dose ganciclovir versus standard dosing for cytomegalovirus viremia in solid organ transplant (SOT) recipients","volume":"7","author":"Fitzmaurice","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0074","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jcv.2005.09.021","article-title":"Is combination antiviral therapy for CMV superior to monotherapy?","volume":"35","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"issue":"19 Suppl 5","key":"10.1016\/j.ijantimicag.2025.107537_bib0075","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2146\/ajhp060379","article-title":"Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients","volume":"63","author":"Cochrane","year":"2006","journal-title":"Am J Health-Syst Pharm"},{"issue":"2","key":"10.1016\/j.ijantimicag.2025.107537_bib0076","doi-asserted-by":"crossref","first-page":"106860","DOI":"10.1016\/j.ijantimicag.2023.106860","article-title":"Management of cytomegalovirus infection in allogeneic hematopoietic stem cell transplants","volume":"62","author":"Allaw","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0077","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4\u2014cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation: ASTCT guidelines on CMV treatment","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0078","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of Ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0079","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0080","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/cid\/ciad709","article-title":"Treatment for first cytomegalovirus infection post\u2013hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with valganciclovir","volume":"78","author":"Papanicolaou","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0081","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/10600280221118959","article-title":"Maribavir for the management of cytomegalovirus in adult transplant recipients: a review of the literature and practical considerations","volume":"57","author":"Kleiboeker","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0082","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0083","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0084","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/cpt.2198","article-title":"Model-informed drug development for anti-infectives: state of the art and future","volume":"109","author":"Rayner","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2016.12.003","article-title":"Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene","volume":"138","author":"Chou","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105792","article-title":"Ganciclovir and maribavir cross-resistance revisited: relative drug susceptibilities of canonical cytomegalovirus mutants","volume":"222","author":"Chou","year":"2024","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.ijantimicag.2025.107537_bib0087","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0088","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-200948060-00006","article-title":"Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements","volume":"48","author":"Perrottet","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0089","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1128\/AAC.36.9.1821","article-title":"Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients","volume":"36","author":"Taburet","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s002280050308","article-title":"Pharmacokinetics and disposition: comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with cytomegalovirus retinitis","volume":"52","author":"Castelli","year":"1997","journal-title":"Eur J Clin Pharamco"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0091","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002239705","article-title":"Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis","volume":"43","author":"Wolf","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ijantimicag.2025.107537_bib0092","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s10928-024-09939-2","article-title":"Population pharmacokinetics and exposure\u2013response relationships of maribavir in transplant recipients with cytomegalovirus infection","volume":"51","author":"Song","year":"2024","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"10.1016\/j.ijantimicag.2025.107537_bib0093","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02684-21","article-title":"Detection of ganciclovir-resistant cytomegalovirus in a prospective cohort of kidney transplant recipients receiving subtherapeutic valganciclovir prophylaxis","volume":"10","author":"Wong","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0094","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0095","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/37.suppl_B.161","article-title":"Surrogate markers in HIV disease","volume":"37","author":"Peto","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0096","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0097","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/FTD.0000000000000598","article-title":"Ganciclovir therapeutic drug monitoring: a case series","volume":"41","author":"M\u00e4rtson","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0098","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007691-200402000-00014","article-title":"Ganciclovir in solid organ transplant recipients is there a role for clinical pharmacokinetic monitoring?","volume":"26","author":"Cates Scott","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0099","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/tid.12317","article-title":"Subtherapeutic ganciclovir (GCV) levels and GCV-resistant cytomegalovirus in lung transplant recipients","volume":"16","author":"Gagermeier","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0100","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/jac\/dky192","article-title":"Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infection","volume":"73","author":"Neant","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0101","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1128\/AAC.04348-14","article-title":"Pharmacokinetics and safety of intravenous cidofovir for life-threatening viral infections in pediatric hematopoietic stem cell transplant recipients","volume":"59","author":"Caruso Brown","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0102","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/AAC.39.6.1247","article-title":"Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients","volume":"39","author":"Cundy","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0103","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/17425255.2018.1550485","article-title":"Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation","volume":"14","author":"Deleenheer","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0104","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1111\/bcp.13292","article-title":"Pharmacokinetics and safety of letermovir, a novel anti-human cytomegalovirus drug, in patients with renal impairment","volume":"83","author":"Kropeit","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0106","first-page":"2253","article-title":"Letermovir breakthroughs during the French named patient programme: interest of monitoring blood concentration in clinical practice","volume":"75","author":"Alain","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105623","article-title":"Prevalence of cytomegalovirus antiviral drug resistance in transplant recipients","volume":"215","author":"Kleiboeker","year":"2023","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0108","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0109","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/jac\/dkab160","article-title":"Application of the hollow fibre infection model (HFIM) in antimicrobial development: a systematic review and recommendations of reporting","volume":"76","author":"Sadouki","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0110","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1093\/jac\/dkx214","article-title":"Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model","volume":"72","author":"Singh","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0111","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1128\/AAC.01385-09","article-title":"In vitro system for modeling influenza A virus resistance under drug pressure","volume":"54","author":"Brown","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0112","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/cpt.2099","article-title":"Toward consensus on correct interpretation of protein binding in plasma and other biological matrices for COVID-19 therapeutic development","volume":"110","author":"Boffito","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0113","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.47.11.3393-3399.2003","article-title":"In vitro-In vivo model for evaluating the antiviral activity of amprenavir in combination with Ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours","volume":"47","author":"Preston","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0114","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/psp4.12681","article-title":"Anti\u2013SARS-CoV-2 repurposing drug database: clinical pharmacology considerations","volume":"10","author":"Zhang","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2025.107537_bib0115","doi-asserted-by":"crossref","first-page":"10709","DOI":"10.1038\/s41598-024-60935-5","article-title":"In-vitro and in-vivo assessment of nirmatrelvir penetration into CSF, central nervous system cells, tissues, and peripheral blood mononuclear cells","volume":"14","author":"Avedissian","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0116","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0117","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jcpt.13585","article-title":"Letermovir and maribavir for pan-resistant cytomegalovirus infection in a patient with haematologic malignancy: consideration for combination therapy","volume":"47","author":"Dickter","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.ijantimicag.2025.107537_bib0118","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14329","article-title":"Successful combination therapy for recurrent refractory cytomegalovirus treatment in a kidney transplant recipient","volume":"26","author":"Marvin","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0119","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/TP.0000000000003260","article-title":"Combination treatment with letermovir and ganciclovir for maintenance therapy of multidrug-resistant CMV infection in a liver transplant recipient","volume":"104","author":"Kronig","year":"2020","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.ijantimicag.2025.107537_bib0120","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/microorganisms9081666","article-title":"Combined therapy with intravenous immunoglobulins, letermovir and (Val-)ganciclovir in complicated courses of cmv-infection in transplant recipients","volume":"9","author":"Di Cristanziano","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0121","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/17512433.2016.1172209","article-title":"Therapeutic drug monitoring of anti-infective agents in critically ill patients","volume":"9","author":"Jager","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0122","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.healun.2019.01.280","article-title":"Does the use of serum ganciclovir levels to adjust valganciclovir dosing prevent the development of CMV resistance in CMV mismatched heart transplant recipients? The Mid America experience","volume":"38","author":"Linard","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.ijantimicag.2025.107537_bib0123","first-page":"1","article-title":"Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults","author":"van Vugt","year":"2024","journal-title":"Br J Clin Pharmacol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:28:48Z","timestamp":1778549328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0924857925000949"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107537","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of drug exposure in the development of cytomegalovirus resistance","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107537"}}